Novartis Debuts Rapidly Manufactured Autologous CAR-Ts

 
• By Alaric DeArment

The company presented early data on two candidates at the ASH meeting that use a less than two-day manufacturing process, YTB323 in diffuse large B-cell lymphoma and PHE885 in multiple myeloma.

3d illustration of T cells or cancer cells
Novartis unveiled early data on its two next-generation CAR-Ts, YTB323 and PHE885 • Source: Shutterstock

More from Immuno-oncology

More from Anticancer